Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SOR-C13||SOR-C13 is a 13-mer peptide derived from soricidin that binds to and inhibits the TRPV6 calcium channel, potentially resulting in decreased tumor growth (PMID: 28150073, PMID: 23554944).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||SOR-C13||Phase I||Actionable||In a Phase I trial, SOR-C13 demonstrated safety and preliminary activity in patients with advanced solid tumors, with treatment resulting in stable disease in 54.5 % (12/22) of patients (PMID: 28150073).||28150073|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03784677||Phase I||SOR-C13||SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors||Recruiting|